Corticosteroid outcome may be dependent of duration of use in severe COVID-19

1. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med 2020;383:120–128.
crossref pmid pmc
2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020;324:782–793.
crossref pmid
3. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020;383:2255–2273.
crossref pmid pmc
4. RECOVERY Collaborative Group; Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med 2021;384:693–704.
crossref pmid pmc
5. REMAP-CAP Investigators; Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med 2021;384:1491–1502.
crossref pmid pmc
6. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med 2021;384:795–807.
pmid
7. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet] Bethesda (MD): National Institutes of Health, 2022. [cited 2022 Feb 9]. Available from: https://www.covid19treatmentguidelines.nih.gov/ . 8. Arabi YM, Chrousos GP, Meduri GU. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Intensive Care Med 2020;46:2067–2070.
crossref pmid pmc pdf
9. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med 2020;46:1603–1606.
crossref pmid pmc pdf
10. Vargas A, Boivin R, Cano P, Murcia Y, Bazin I, Lavoie JP. Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma. Respir Res 2017;18:207.
crossref pmid pmc pdf
11. Fleishaker DL, Mukherjee A, Whaley FS, Daniel S, Zeiher BG. Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study. BMC Musculoskelet Disord 2016;17:293.
crossref pmid pmc
12. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007;131:954–963.
crossref pmid
13. COVID STEROID 2 Trial Group; Munch MW, Myatra SN, et al. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial. JAMA 2021;326:1807–1817.
pmid
14. Granholm A, Munch MW, Myatra SN, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Med 2022;48:45–55.
crossref pmid pmc pdf
15. Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA 2020;324:1298–1306.
crossref pmid pmc
16. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA 2020;324:1307–1316.
crossref pmid pmc
17. Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020;324:1317–1329.
crossref pmid pmc
18. Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr 2021;133:303–311.
crossref pmid pmc pdf
19. Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 2021;21:337.
crossref pmid pmc pdf
20. Rubio-Rivas M, Mora-Luján JM, Formiga F, et al. WHO ordinal scale and inflammation risk categories in COVID-19. Comparative study of the severity scales. J Gen Intern Med; 37:1980–1987.
crossref pmid pdf
21. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.
crossref pmid pmc pdf
22. Prowle JR, Echeverri JE, Ligabo EV, et al. Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care 2011;15:R100.
crossref
23. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61–e111.
crossref pdf
24. Moreno G, Carbonell R, Martin-Loeches I, et al. Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study. Ann Intensive Care 2021;11:159.
crossref pmid pmc pdf
25. Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ 2020;192:E756–E767.
crossref
26. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020;324:1330–1341.
pmid
27. Cano EJ, Fonseca Fuentes X, Corsini Campioli C, et al. Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta-analysis. Chest 2021;159:1019–1040.
crossref pmid pmc
28. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020;20:1135–1140.
crossref pmid
29. Schaller T, Hirschbühl K, Burkhardt K, et al. Postmortem examination of patients with COVID-19. JAMA 2020;323:2518–2520.
crossref pmid pmc
30. Meduri GU, Bridges L, Shih MC, Marik PE, Siemieniuk RAC, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med 2016;42:829–840.
crossref pmid pdf
31. Chaudhuri D, Sasaki K, Karkar A, et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med 2021;47:521–537.
crossref pmid pmc pdf
32. Meduri GU, Annane D, Confalonieri M, et al. Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Intensive Care Med 2020;46:2284–2296.
crossref pmid pmc pdf
33. Kostorz-Nosal S, Jastrzębski D, Chyra M, Kubicki P, Zieliński M, Ziora D. A prolonged steroid therapy may be beneficial in some patients after the COVID-19 pneumonia. Eur Clin Respir J 2021;8:1945186.
crossref pmid pmc
34. Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc 2021;18:799–806.
crossref pmid pmc
35. Seo H, Jung J, Kim MJ, Jang SJ, Kim SH. Radiologically suspected organizing pneumonia in a patient recovering from COVID-19: a case report. Infect Chemother 2022;54:208–212.
crossref pmid pmc pdf
36. Bieksiene K, Zaveckiene J, Malakauskas K, Vaguliene N, Zemaitis M, Miliauskas S. Post COVID-19 organizing pneumonia: the right time to interfere. Medicina (Kaunas) 2021;57:283.
crossref pmid pmc
37. Kory P, Kanne JP. SARS-CoV-2 organising pneumonia: ‘has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’. BMJ Open Respir Res 2020;7:e000724.
crossref pmid pmc
38. Golbets E, Kaplan A, Shafat T, et al. Secondary organizing pneumonia after recovery of mild COVID-19 infection. J Med Virol 2022;94:417–423.
crossref pdf
39. Cordier JF. Organising pneumonia. Thorax 2000;55:318–328.
pmid pmc
40. Cordier JF. Cryptogenic organising pneumonia. Eur Respir J 2006;28:422–446.
crossref pmid
41. Patel A, Kaur H, Xess I, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 2020;26:944e9–e15.
crossref pmid
42. Hirano Y, Madokoro S, Kondo Y, Okamoto K, Tanaka H. Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. J Intensive Care 2020;8:91.
crossref pmid pmc pdf
43. Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res 2019;6:e000420.
crossref pmid pmc
44. Brotman DJ, Girod JP, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 2006;118:247–252.
crossref pmid
45. Mishra GP, Mulani J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. Lancet Respir Med 2021;9:e8.
crossref pmid

留言 (0)

沒有登入
gif